<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01401985</url>
  </required_header>
  <id_info>
    <org_study_id>TD-1211-0076</org_study_id>
    <nct_id>NCT01401985</nct_id>
  </id_info>
  <brief_title>A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)</brief_title>
  <official_title>A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects With Opioid-Induced Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects&#xD;
      with Opioid-Induced Constipation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of TD-1211</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete spontaneous bowel movements (CSBM); Spontaneous bowel movements (SBM)</measure>
    <time_frame>Weekly assessments throughout Treatment Period</time_frame>
    <description>Change from baseline in the weekly SBM and CSBM frequency</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Opioid Induced Constipation</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg TD-1211 once daily for 4 days followed by 10 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg TD-1211 once daily for 4 days followed by 15 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg TD-1211 once daily for 2 days followed by 10 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg TD-1211 once daily for 2 days followed by 15 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg TD-1211 once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg TD-1211 every 6 hours for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  stable dose of opioids for at least 12 weeks before screening visit&#xD;
&#xD;
          -  less than or equal to 5 spontaneous bowel movements for a 2 week period and&#xD;
             experiencing at least one other symptom of constipation&#xD;
&#xD;
          -  willing to stop laxatives and other bowel treatments; rescue laxative allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant condition or illness (other than the condition for which the&#xD;
             pain medication was prescribed)&#xD;
&#xD;
          -  Have participated in another clinical trial of an investigational drug 30 days prior&#xD;
             to screening&#xD;
&#xD;
          -  History of cancer treatment except adequately treated localized skin cancer within 5&#xD;
             years of screening&#xD;
&#xD;
          -  History of chronic constipation prior to opioid therapy&#xD;
&#xD;
          -  Females who are pregnant or breast feeding&#xD;
&#xD;
          -  Have any condition that may affect drug absorption (e.g. previous GI surgery)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <disposition_first_submitted>June 5, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>June 5, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 13, 2013</disposition_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid induced constipation</keyword>
  <keyword>OIC</keyword>
  <keyword>Constipation</keyword>
  <keyword>Opioid side effects</keyword>
  <keyword>morphine induced constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Opioid-Induced Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

